Financial reports
ARS
2023 FY
Annual report to shareholders
2 Apr 24
10-K
2023 FY
Annual report
27 Feb 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
10-Q
2023 Q1
Quarterly report
8 May 23
ARS
2022 FY
Annual report to shareholders
7 Apr 23
10-K
2022 FY
Annual report
28 Feb 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
10-Q
2022 Q1
Quarterly report
9 May 22
Current reports
8-K
Syndax Announces Appointment of Steven Closter as Chief Commercial Officer
18 Mar 24
8-K
Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
27 Feb 24
8-K
Syndax Announces Closing of Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
20 Dec 23
8-K
Entry into a Material Definitive Agreement
15 Dec 23
8-K
Other Events
12 Dec 23
8-K
Syndax Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update
2 Nov 23
8-K
Other Events
2 Oct 23
8-K
Syndax Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update
3 Aug 23
8-K
Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease
24 Jul 23
8-K
Termination of a Material Definitive Agreement
26 May 23
Registration and prospectus
S-3ASR
Automatic shelf registration
27 Feb 24
S-8
Registration of securities for employees
27 Feb 24
424B5
Prospectus supplement for primary offering
15 Dec 23
424B5
Prospectus supplement for primary offering
14 Dec 23
424B5
Prospectus supplement for primary offering
26 May 23
S-8
Registration of securities for employees
28 Feb 23
424B5
Prospectus supplement for primary offering
7 Dec 22
424B5
Prospectus supplement for primary offering
6 Dec 22
S-8
Registration of securities for employees
1 Mar 22
424B5
Prospectus supplement for primary offering
17 Dec 21
Proxies
DEFA14A
Additional proxy soliciting materials
2 Apr 24
DEF 14A
Definitive proxy
2 Apr 24
DEFA14A
Additional proxy soliciting materials
18 Apr 23
DEFA14A
Additional proxy soliciting materials
7 Apr 23
DEF 14A
Definitive proxy
7 Apr 23
PRE 14A
Preliminary proxy
28 Mar 23
DEFA14A
Additional proxy soliciting materials
30 Mar 22
DEF 14A
Definitive proxy
29 Mar 22
DEF 14A
Definitive proxy
1 Apr 21
DEF 14A
Definitive proxy
29 Apr 20
Other
UPLOAD
Letter from SEC
7 Dec 23
CORRESP
Correspondence with SEC
28 Nov 23
UPLOAD
Letter from SEC
13 Nov 23
EFFECT
Notice of effectiveness
11 Sep 19
CORRESP
Correspondence with SEC
6 Sep 19
UPLOAD
Letter from SEC
5 Sep 19
CT ORDER
Confidential treatment order
28 Mar 19
CT ORDER
Confidential treatment order
20 Dec 18
CT ORDER
Confidential treatment order
27 Nov 18
CT ORDER
Confidential treatment order
29 Aug 18
Ownership
SC 13G
Kynam Capital Management, LP
14 Feb 24
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 24
SC 13G/A
Avidity Partners Management LP
13 Feb 24
SC 13G
VANGUARD GROUP INC
13 Feb 24
4
Michael A Metzger
9 Feb 24
4
Keith A. Goldan
9 Feb 24
4
Neil Gallagher
9 Feb 24
4
Martin H. Jr. Huber
9 Feb 24
4
Jennifer Jarrett
9 Feb 24
4
Keith Katkin
9 Feb 24